News and Trends 15 Oct 2014
Recently Launched Company Rigontec already Raised 9,45M Euros against Cancer
Rigontec GmbH, a German privately held biopharmaceutical company developing RNA-based immunotherapeutics for the treatment of cancer and viral diseases, announced the first closing of its Series A financing round, raising €9.45 million. Rigontec was launched in January 2014 as a spin-out of the Institute for Clinical Chemistry and Clinical Pharmacology at the University of Bonn, Germany. The Company’s […]
